AMRX Q1 2019 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$446M+62.1% YoY

Gross Profit

$83M18.6% margin

Operating Income

-$94M-21.2% margin

Net Income

-$48M-10.7% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-10.3%

Cash Flow

Operating Cash Flow

-$108M

Free Cash Flow

-$126M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$3.6B

Stockholders' Equity

$472M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$446M	$275M	+62.1%
Gross Profit	$83M	$145M	-42.5%
Operating Income	-$94M	$64M	-248.5%
Net Income	-$48M	$52M	-192.9%

Revenue Segments

Levothyroxine Sodium

$49M36%

Rytary Family

$29M21%

Diclofenac Sodium Gel

$23M17%

Yuvafem-Estradiol

$19M14%

Epinephrine Auto-Injector Family (Generic Adrenaclick)

$15M11%